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Introduction
Management of advanced B cell malignancies refractory to
standard chemotherapy is challenging with sub-optimal
results. Recent clinical reports of durable, objective
responses from adoptive transfer of anti-CD19 chimeric
antigen receptor (CAR) T cells have accentuated the
potential of this therapy.
Here we report the preliminary results of an on-going
Phase I clinical trial at our Institution.
Methods
This is a single centre, open label, dose escalation, Phase I
study of adoptive transfer of autologous T cells expressing
a CD19-specific first generation CAR (aCD19z) with
pre-conditioning chemotherapy and intravenous interleu-
kin-2 (IL2), in patients with pre-treated CD19-positive
malignancy.
We report data on 2 cohorts: Cohort 1 (4 patients)
received 1x109 aCD19z T-cells and Cohort 2 (planned
4 patients) 1x1010. Both cohorts received 100,000 u/kg
of IL2.
Results
To date, 6 patients have successfully completed treatment.
All patients tolerated treatment well, and experienced
anticipated transient grade1-2 toxicities attributable to
pre-conditioning chemotherapy and IL2. 5 patients
developed short lived but significant Grade 4 neutropenia
and thrombocytopenia.
4 of 5 patients evaluable to date achieved at least stable
disease as best response at 6 weeks post aCD19z T cell
infusion, with 1 patient maintaining response at 400+
days. 1 patient achieved a very good partial response with
a 65% reduction in disease burden. 2 patients died of dis-
ease progression (1 of Central Nervous (CN) progression
only, not present at baseline); 2 patients died of viral infec-
tion over 400 days post infusion; 1 patient with disease
control maintained. No patients died of treatment-related
complications.
Quantitative polymerase chain reaction (qPCR) analysis
of peripheral blood samples detected aCD19z T cells in
both cohorts. Levels peaked at days 4-7 post aCD19z T
cell infusion (cohort 1 peak 30% of total cells, cohort 2
(results available to date) peak 25%) before falling to lower
levels. All patients revealed persisting low frequency levels
(<1%) at week 6; 1 patient at up to 50 weeks. 1 patient
received a further course of low dose IL2 at week 6 result-
ing in a transient increase in zCD19z T cell levels.
All patients demonstrated a significant reduction in
peripheral CD19+ T cell numbers post aCD19z T cell
infusion, with most substantial results seen in cohort 2
where suppression was seen lasting into week 8 (prior to
CN progression).
Discussion
Our data contributes to the encouraging growing body of
evidence on antiCD19-specific CAR T cells, suggesting
significant clinical responses and sustained persistence.
Updated results and immune data will be presented.
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